Investors

We’re happy to share that Johan van Wyk, Resident Director of Cyclarity Therapeutics Australia Pty Ltd, represented Cyclarity on the clinical panel at AusBiotech 2025 Conference. He discussed the clinical progress of Cyclarity’s UDP-003 and explained why Australia was chosen as the strategic location for conducting Phase 1 trials.

NOVATO, Calif., Jan. 09, 2025

Cyclarity Therapeutics, Inc. (“Cyclarity”), announces the closing of the first tranche of its Series A funding round, led by Ki Tua Fund LP and Starbloom Primrose LP.

Cyclarity will use funds from this round to commence clinical trials later this month for the development of UDP-003, a novel therapeutic designed to reduce atherosclerotic plaque accumulation by targeting its root cause, the accumulation of toxic oxidized cholesterol in cells and tissues.

Characterized by plaque accumulation in the arteries, atherosclerosis is the main contributor to cardiovascular diseases, including heart attack and stroke, and is responsible for up to 44% of all deaths worldwide. “We’re in the clinic,” noted Matthew O’Connor, CEO of Scientific Affairs, “with a drug that has the potential not only to treat atherosclerosis, but to reverse and repair it. It’s a first, and we’re very proud of this step.”

Tranche 1 comprised ~$6.4M USD. Tranche 2, expected to raise $2.6-5.6M, will fund the patient portion of the trial. That tranche is partially committed and is expected to close soon.